AR065587A1 - Aminoamidas como antagonistas de orexina - Google Patents
Aminoamidas como antagonistas de orexinaInfo
- Publication number
- AR065587A1 AR065587A1 ARP080100889A ARP080100889A AR065587A1 AR 065587 A1 AR065587 A1 AR 065587A1 AR P080100889 A ARP080100889 A AR P080100889A AR P080100889 A ARP080100889 A AR P080100889A AR 065587 A1 AR065587 A1 AR 065587A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- halogen
- hydrogen
- hydroxy
- Prior art date
Links
- SDCMHPPKMQZPPJ-UHFFFAOYSA-N 3-phenyl-4h-quinazoline Chemical compound C1=NC2=CC=CC=C2CN1C1=CC=CC=C1 SDCMHPPKMQZPPJ-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000002512 Orexin Human genes 0.000 abstract 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- -1 cyano, 3-hydroxy-oxetan-3-yl Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 108060005714 orexin Proteins 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de la formula (1) en la que Ar1, Ar2 y Ar3 con independencia entre sí son arilo o heteroarilo sin sustituir o sustituidos; R1, R2 y R3 con independencia entre sí son hidroxi, halogeno, alquilo inferior, alquiloinferior sustituido por halogeno, alcoxi inferior, alcoxi inferior sustituido por halogeno, ciano, 3-hidroxi-oxetan-3-ilo, SO2-alquilo inferior o di-alquilo inferior-amino; R4/R5 con independencia entre sí son hidrogeno, alquilo inferior, alquiloinferior sustituido por halogeno, alquilo inferior sustituido por hidroxi, -(CH2)o-O-alquilo inferior, -(CH2)o-N-(alquilo inferior)2, (CH2)p-cicloalquilo, (CH2)p-arilo, dicho anillo arilo puede estar sustituido por halogeno, o R4 y R5 junto con elátomo de N al que están unidos pueden formar un anillo heterocíclico, opcionalmente con otros heteroátomos del anillo elegidos entre N, O y S; R6 es hidrogeno o alquilo inferior; R7es hidrogeno o alquilo inferior; R8 es hidrogeno o ciano; n es elnumero 0, 1, 2 o 3; o es el numero 1, 2 o 3; p es el numero 0, 1 o 2; o las sales de adicion de ácido farmacéuticamente idoneas, enantiomeros opticamente puros, racematos o mezclas diastereoméricas de los mismos. Ahora se ha encontrado que loscompuestos de la formula 1 son antagonistas de receptor de orexina y los compuestos en cuestion pueden ser utiles para el tratamiento de trastornos, en los que intervienen los mecanismos de la orexina, por ejemplo los trastornos de sueno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103521 | 2007-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065587A1 true AR065587A1 (es) | 2009-06-17 |
Family
ID=39401194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100889A AR065587A1 (es) | 2007-03-05 | 2008-03-03 | Aminoamidas como antagonistas de orexina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7829563B2 (es) |
| EP (1) | EP2114867B1 (es) |
| JP (1) | JP5138708B2 (es) |
| KR (1) | KR101132534B1 (es) |
| CN (1) | CN101627007A (es) |
| AR (1) | AR065587A1 (es) |
| AU (1) | AU2008223916A1 (es) |
| BR (1) | BRPI0808348A2 (es) |
| CA (1) | CA2679039A1 (es) |
| CL (1) | CL2008000641A1 (es) |
| IL (1) | IL200402A0 (es) |
| MX (1) | MX2009009121A (es) |
| PE (1) | PE20081876A1 (es) |
| TW (1) | TW200843729A (es) |
| WO (1) | WO2008107335A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110025915A (ko) * | 2008-06-16 | 2011-03-14 | 에프. 호프만-라 로슈 아게 | 오렉시닌 수용체 길항제로서 헤테로방향족 모노아마이드 |
| JP6012468B2 (ja) | 2009-10-02 | 2016-10-25 | アヴェクシン エーエス | 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール |
| CN103347517B (zh) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
| EP2811997B1 (en) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| JP6371312B2 (ja) | 2013-01-29 | 2018-08-08 | アヴェクシン エーエス | 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物 |
| ES2769780T3 (es) | 2013-10-28 | 2020-06-29 | Univ Drexel | Tratamientos novedosos para los trastornos de atención y cognitivos y para la demencia asociada a un trastorno neurodegenerativo |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| AR101558A1 (es) | 2014-08-13 | 2016-12-28 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
| HUE059280T2 (hu) | 2016-02-12 | 2022-11-28 | Astrazeneca Ab | Halogén-szubsztituált piperidinek mint orexin receptor modulátorok |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| EP3454857A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
| WO2019205147A1 (zh) * | 2018-04-28 | 2019-10-31 | 上海璃道医药科技有限公司 | 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290799A (en) * | 1990-09-19 | 1994-03-01 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| GB9727521D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| KR20020075396A (ko) * | 2000-01-28 | 2002-10-04 | 멜라큐어 테라퓨틱스 에이비 | 신규의 멜라노코르틴 수용체 효능제 및 길항제 |
| EP1193248A1 (en) * | 2000-09-30 | 2002-04-03 | Aventis Pharma Deutschland GmbH | Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
| DK1362844T3 (da) * | 2001-01-26 | 2008-04-14 | Btg Int Ltd | Benzylaminanalog |
| GB0126292D0 (en) * | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| US7538109B2 (en) * | 2003-04-28 | 2009-05-26 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-one derivatives as orexin receptor antagonists |
| US7163942B2 (en) * | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
-
2008
- 2008-02-25 WO PCT/EP2008/052245 patent/WO2008107335A1/en not_active Ceased
- 2008-02-25 CN CN200880007171A patent/CN101627007A/zh active Pending
- 2008-02-25 AU AU2008223916A patent/AU2008223916A1/en not_active Abandoned
- 2008-02-25 MX MX2009009121A patent/MX2009009121A/es active IP Right Grant
- 2008-02-25 JP JP2009552167A patent/JP5138708B2/ja not_active Expired - Fee Related
- 2008-02-25 KR KR1020097018404A patent/KR101132534B1/ko not_active Expired - Fee Related
- 2008-02-25 EP EP08717082A patent/EP2114867B1/en not_active Not-in-force
- 2008-02-25 CA CA002679039A patent/CA2679039A1/en not_active Abandoned
- 2008-02-25 BR BRPI0808348-7A patent/BRPI0808348A2/pt not_active IP Right Cessation
- 2008-02-27 US US12/037,975 patent/US7829563B2/en not_active Expired - Fee Related
- 2008-03-03 PE PE2008000423A patent/PE20081876A1/es not_active Application Discontinuation
- 2008-03-03 AR ARP080100889A patent/AR065587A1/es unknown
- 2008-03-03 TW TW097107367A patent/TW200843729A/zh unknown
- 2008-03-04 CL CL200800641A patent/CL2008000641A1/es unknown
-
2009
- 2009-08-13 IL IL200402A patent/IL200402A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200843729A (en) | 2008-11-16 |
| JP2010520252A (ja) | 2010-06-10 |
| KR20090107083A (ko) | 2009-10-12 |
| IL200402A0 (en) | 2010-04-29 |
| CL2008000641A1 (es) | 2008-09-12 |
| BRPI0808348A2 (pt) | 2014-07-15 |
| CN101627007A (zh) | 2010-01-13 |
| MX2009009121A (es) | 2009-09-03 |
| KR101132534B1 (ko) | 2012-08-22 |
| EP2114867A1 (en) | 2009-11-11 |
| PE20081876A1 (es) | 2008-12-27 |
| CA2679039A1 (en) | 2008-09-12 |
| US7829563B2 (en) | 2010-11-09 |
| US20080221166A1 (en) | 2008-09-11 |
| EP2114867B1 (en) | 2012-12-12 |
| JP5138708B2 (ja) | 2013-02-06 |
| AU2008223916A1 (en) | 2008-09-12 |
| WO2008107335A1 (en) | 2008-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065587A1 (es) | Aminoamidas como antagonistas de orexina | |
| AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
| AR069849A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| PE20071311A1 (es) | Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu | |
| CR9078A (es) | Derivado de bencimidazol ariloxi-sustituidos | |
| PA8783501A1 (es) | Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| AR070558A1 (es) | Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas. | |
| AR066509A1 (es) | Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide. | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| NI201300074A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos. | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR053301A1 (es) | Derivados de pirazina y su uso farmaceutico | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| PE20081468A1 (es) | Derivados de tetrahidropirimidin-5-carboxamida como inhibidores de mapk/erk quinasa | |
| AR075534A1 (es) | Derivados de piridazinona sustituida por heteroarilo | |
| AR065904A1 (es) | Heterociclos como antagonistas de orexina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |